Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) just unveiled an announcement.
Biocytogen Pharmaceuticals has established a Remuneration and Evaluation Committee under its board of directors to improve its corporate governance structure. This committee is tasked with formulating evaluation standards and reviewing remuneration policies for the company’s directors and senior management, thereby ensuring accountability and strategic alignment with the company’s goals.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a pharmaceutical company incorporated in China, focusing on enhancing its core competitiveness and optimizing corporate governance through a comprehensive remuneration and evaluation system for its directors and senior management.
Average Trading Volume: 523,150
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.78B
For a thorough assessment of 2315 stock, go to TipRanks’ Stock Analysis page.